Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in many cancer cells without causing toxicity in vivo. However, to date, TRAIL-receptor agonists have only shown limited therapeutic benefit in clinical trials. This can, most likely, be attributed to the fact that 50% of all cancer cell lines and most primary human cancers are TRAIL resistant. Consequently, future TRAIL-based therapies will require the addition of sensitizing agents that remove crucial blocks in the TRAIL apoptosis pathway. Here, we identify PIK-75, a small molecule inhibitor of the p110α isoform of phosphoinositide-3 kinase (PI3K), as an exceptionally potent TRAIL apoptosis sensitizer. Surprisingly, PI3K inhibition was not responsible for this activity. A kinome-wide in vitro screen revealed that PIK-75 strongly inhibits a panel of 27 kinases in addition to p110α. Within this panel, we identified cyclin-dependent kinase 9 (CDK9) as responsible for TRAIL resistance of cancer cells. Combination of CDK9 inhibition with TRAIL effectively induced apoptosis even in highly TRAIL-resistant cancer cells. Mechanistically, CDK9 inhibition resulted in downregulation of cellular FLICE-like inhibitory protein (cFlip) and Mcl-1 at both the mRNA and protein levels. Concomitant cFlip and Mcl-1 downregulation was required and sufficient for TRAIL sensitization by CDK9 inhibition. When evaluating cancer selectivity of TRAIL combined with SNS-032, the most selective and clinically used inhibitor of CDK9, we found that a panel of mostly TRAIL-resistant non-small cell lung cancer cell lines was readily killed, even at low concentrations of TRAIL. Primary human hepatocytes did not succumb to the same treatment regime, defining a therapeutic window. Importantly, TRAIL in combination with SNS-032 eradicated established, orthotopic lung cancer xenografts in vivo. Based on the high potency of CDK9 inhibition as a cancer cell-selective TRAIL-sensitizing strategy, we envisage the development of new, highly effective cancer therapies.

[1]  W. Plunkett,et al.  Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. , 2009, Blood.

[2]  Henning Walczak,et al.  TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.

[3]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[4]  G. Salvesen,et al.  Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.

[5]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[6]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[7]  Louise Fairall,et al.  A Death Effector Domain Chain DISC Model Reveals a Crucial Role for Caspase-8 Chain Assembly in Mediating Apoptotic Cell Death , 2012, Molecular cell.

[8]  W. Plunkett,et al.  Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[10]  H. Wajant,et al.  Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation , 2010, Cell Death and Differentiation.

[11]  R. Fisher.  Secrets of a double agent: CDK7 in cell-cycle control and transcription , 2005, Journal of Cell Science.

[12]  M. Todaro,et al.  Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4 , 2008, Cell Death and Differentiation.

[13]  C. Rommel,et al.  Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. , 2006, Journal of medicinal chemistry.

[14]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Robertson,et al.  PI 3-kinase p110beta: a new target for antithrombotic therapy. , 2005, Nature medicine.

[16]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[17]  Michael W. Parker,et al.  Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. , 2013, Blood.

[18]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[19]  J. Blenis,et al.  Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8* , 2001, The Journal of Biological Chemistry.

[20]  S. Fulda,et al.  Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma , 2011, Clinical Cancer Research.

[21]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[22]  Malini Guha,et al.  Cyclin-dependent kinase inhibitors move into Phase III , 2012, Nature Reviews Drug Discovery.

[23]  Julian Downward,et al.  The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer , 2012, Cell.

[24]  John Calvin Reed.  Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. , 1995, Current opinion in oncology.

[25]  J. Tabernero,et al.  Development of PI3K inhibitors: lessons learned from early clinical trials , 2013, Nature Reviews Clinical Oncology.

[26]  Ting Zhou,et al.  Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis , 2010, Bioinform..

[27]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[28]  B. Peterlin,et al.  Controlling the elongation phase of transcription with P-TEFb. , 2006, Molecular cell.

[29]  P. Krammer,et al.  Cellular FLICE-inhibitory Protein Splice Variants Inhibit Different Steps of Caspase-8 Activation at the CD95 Death-inducing Signaling Complex* , 2001, The Journal of Biological Chemistry.

[30]  R. K Srivastava,et al.  Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL , 2007, Cancer Chemotherapy and Pharmacology.

[31]  A. López-Rivas,et al.  Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. , 2006, Cancer research.

[32]  Gary Box,et al.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.

[33]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[34]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[35]  L. Andĕra,et al.  Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis , 2013, Leukemia & lymphoma.

[36]  Peter M Fischer,et al.  Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. , 2008, Trends in pharmacological sciences.

[37]  H. Walczak,et al.  Is TRAIL the holy grail of cancer therapy? , 2009, Apoptosis.

[38]  H. Walczak,et al.  Biochemical analysis of the native TRAIL death-inducing signaling complex. , 2008, Methods in molecular biology.

[39]  A. Mittelman,et al.  Phase I clinical trial of recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.

[40]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[41]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[42]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[43]  Patricia M. LoRusso,et al.  A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors , 2008, Investigational New Drugs.

[44]  H. Wakimoto,et al.  A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. , 2011, Cancer research.

[45]  R. Maria,et al.  Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism , 2008, Cell Research.

[46]  A. Grosse-Wilde,et al.  Caspase‐10 is recruited to and activated at the native TRAIL and CD95 death‐inducing signalling complexes in a FADD‐dependent manner but can not functionally substitute caspase‐8 , 2002, The EMBO journal.

[47]  Andreas Untergasser,et al.  Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs , 2006, Clinical Cancer Research.

[48]  D. Lawrence,et al.  Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. , 2000, Immunity.

[49]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[50]  Yves Pommier,et al.  Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks , 2004, Oncogene.

[51]  Bernd Giese,et al.  Targeting phosphoinositide 3-kinase: moving towards therapy. , 2008, Biochimica et biophysica acta.

[52]  M. Arkin,et al.  SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples , 2009, Cancer Chemotherapy and Pharmacology.

[53]  O. Bensaude,et al.  Inhibiting eukaryotic transcription. Which compound to choose? How to evaluate its activity? , 2011, Transcription.

[54]  W. Denny,et al.  A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types , 2011, The Biochemical journal.

[55]  D. Price,et al.  Control of RNA Polymerase II Elongation Potential by a Novel Carboxyl-terminal Domain Kinase* , 1996, The Journal of Biological Chemistry.

[56]  Eun Hee Kim,et al.  Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP , 2004, Oncogene.

[57]  Christoph Borner,et al.  XIAP discriminates between type I and type II FAS-induced apoptosis , 2009, Nature.

[58]  J. Blenis,et al.  FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. , 2000, Immunity.

[59]  F. Dufour,et al.  Death receptors as targets in cancer , 2013, British journal of pharmacology.